This is a StreetInsider.com Premium Only Page

(FRLN) –

Mar 1, 2024 04:06 PM Form 15-12G Freeline Therapeutics

Feb 26, 2024 06:02 AM Form EFFECT Freeline Therapeutics

Feb 22, 2024 04:38 PM Form S-8 POS Freeline Therapeutics

Feb 22, 2024 04:37 PM Form S-8 POS Freeline Therapeutics

Feb 22, 2024 04:33 PM Form S-8 POS Freeline Therapeutics

Feb 22, 2024 04:33 PM Form S-8 POS Freeline Therapeutics

Feb 22, 2024 04:29 PM Form POS AM Freeline Therapeutics

Feb 22, 2024 04:06 PM Form SC 13D/A Freeline Therapeutics Filed by: Syncona Portfolio Ltd

Feb 20, 2024 03:23 PM Form SC 13E3/A Freeline Therapeutics Filed by: Freeline Therapeutics Holdings plc

Feb 20, 2024 12:04 PM Form 25-NSE Freeline Therapeutics Filed by: Nasdaq Stock Market LLC

Feb 20, 2024 07:14 AM Form 6-K Freeline Therapeutics For: Feb 20

Feb 20, 2024 07:08 AM Acquisition of Freeline (FRLN) by Syncona Becomes Effective

Feb 20, 2024 07:00 AM Acquisition of Freeline by Syncona Becomes Effective

Feb 14, 2024 12:16 PM Form SC 13G/A Freeline Therapeutics Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Feb 12, 2024 04:24 PM Form SC 13G/A Freeline Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Feb 12, 2024 04:02 PM Form 6-K Freeline Therapeutics For: Feb 12

Feb 12, 2024 12:00 PM Freeline Shareholders Approve Acquisition by Syncona

Jan 31, 2024 04:11 PM Form SC 13G/A Freeline Therapeutics Filed by: Tetragon Financial Management LP

Jan 18, 2024 04:16 PM Form 6-K Freeline Therapeutics For: Jan 18

Jan 17, 2024 04:18 PM Form SC 13E3/A Freeline Therapeutics Filed by: Freeline Therapeutics Holdings plc

Dec 8, 2023 05:22 PM Form SC 13E3 Freeline Therapeutics Filed by: Freeline Therapeutics Holdings plc

Dec 1, 2023 08:56 AM Form 6-K Freeline Therapeutics For: Sep 30

Nov 28, 2023 06:08 AM H.C. Wainwright Downgrades Freeline (FRLN) to Neutral

Nov 24, 2023 07:31 AM Form SC 13D/A Freeline Therapeutics Filed by: Syncona Portfolio Ltd

Nov 22, 2023 09:21 AM Form 6-K Freeline Therapeutics For: Nov 22

Nov 22, 2023 07:30 AM Freeline (FRLN) Acquired by Syncona for $6.50/sh

Nov 22, 2023 07:30 AM Syncona to Acquire Freeline Therapeutics

Nov 22, 2023 07:25 AM Freeline Therapeutics Holdings (FRLN) Halted, News Pending

Oct 25, 2023 06:02 AM Form 6-K Freeline Therapeutics For: Oct 25

Oct 25, 2023 02:01 AM Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Oct 18, 2023 08:10 AM Wedbush Downgrades Freeline (FRLN) to Neutral

Oct 18, 2023 07:00 AM Form 6-K Freeline Therapeutics For: Oct 18

Oct 18, 2023 06:05 AM Form SC 13D/A Freeline Therapeutics Filed by: Syncona Portfolio Ltd

Oct 16, 2023 07:00 AM Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress

Oct 6, 2023 04:52 PM Form 6-K Freeline Therapeutics For: Oct 06

Oct 4, 2023 07:00 AM Freeline Therapeutics Holdings (FRLN) Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201

Oct 4, 2023 07:00 AM Form 6-K Freeline Therapeutics For: Oct 04

Oct 4, 2023 07:00 AM Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Aug 15, 2023 04:16 PM Freeline (FRLN) PT Raised to $4 at Stifel

Aug 15, 2023 07:01 AM Form 6-K Freeline Therapeutics For: Jun 30

Aug 15, 2023 07:00 AM Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023 07:30 AM Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

Jul 31, 2023 07:30 AM Freeline to Participate in Upcoming Investor Conferences

Jul 25, 2023 07:30 AM Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

Jul 17, 2023 04:50 PM Form SC 13G Freeline Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Jun 30, 2023 06:03 AM Form 6-K Freeline Therapeutics For: Jun 29

Jun 26, 2023 07:31 AM Form 6-K Freeline Therapeutics For: Jun 26

Jun 26, 2023 07:30 AM Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

Jun 2, 2023 08:00 AM Freeline to Present at 2023 Jefferies Healthcare Conference

May 31, 2023 04:45 PM Form 6-K Freeline Therapeutics For: May 31